Gigaxonin Antibody (F-11): sc-390067

Gigaxonin Antibody (F-11) is a mouse monoclonal IgG2a antibody that detects gigaxonin in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Gigaxonin plays a crucial role in maintaining neuronal function and survival by regulating protein degradation, which is vital for the proper organization and dynamics of the cytoskeleton. As a member of the cytoskeletal BTB/kelch repeat family, gigaxonin is instrumental in the architecture of neurofilaments, with its amino terminal BTB domain binding to the ubiquitin-activating enzyme E1, while the carboxy-terminal kelch repeat domain interacts with the light chain of microtubule-associated protein 1B (MAP1B) to tag MAP1B for degradation. The balance of MAP1B levels is critical, as MAP1B overexpression can lead to neuronal cell death, whereas a reduction significantly enhances neuronal survival. Mutations in gigaxonin are linked to giant axonal neuropathy (GAN), an autosomal recessive neurodegenerative disorder characterized by axonal degeneration due to cytoskeletal abnormalities, including the accumulation of intermediate filaments. Anti-gigaxonin antibody (F-11) is an essential tool for researchers studying the mechanisms of neurodegeneration and the role of cytoskeletal proteins in neuronal health.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Gigaxonin Antibody (F-11) References:

1. Microtubule-associated protein 1B: a neuronal binding partner for gigaxonin.  |  Ding, J., et al. 2002. J Cell Biol. 158: 427-33. PMID: 12147674
2. Gigaxonin interacts with tubulin folding cofactor B and controls its degradation through the ubiquitin-proteasome pathway.  |  Wang, W., et al. 2005. Curr Biol. 15: 2050-5. PMID: 16303566
3. Gigaxonin controls vimentin organization through a tubulin chaperone-independent pathway.  |  Cleveland, DW., et al. 2009. Hum Mol Genet. 18: 1384-94. PMID: 19168853
4. Gigaxonin mutation analysis in patients with NIFID.  |  Dequen, F., et al. 2011. Neurobiol Aging. 32: 1528-9. PMID: 19782434
5. Giant axonal neuropathy-associated gigaxonin mutations impair intermediate filament protein degradation.  |  Mahammad, S., et al. 2013. J Clin Invest. 123: 1964-75. PMID: 23585478
6. Giant axonal neuropathy.  |  Hentati, F., et al. 2013. Handb Clin Neurol. 115: 933-8. PMID: 23931822
7. p16 Protein and gigaxonin are associated with the ubiquitination of NFκB in cisplatin-induced senescence of cancer cells.  |  Veena, MS., et al. 2014. J Biol Chem. 289: 34921-37. PMID: 25331947
8. The role of gigaxonin in the degradation of the glial-specific intermediate filament protein GFAP.  |  Lin, NH., et al. 2016. Mol Biol Cell. 27: 3980-3990. PMID: 27798231
9. HILI destabilizes microtubules by suppressing phosphorylation and Gigaxonin-mediated degradation of TBCB.  |  Tan, H., et al. 2017. Sci Rep. 7: 46376. PMID: 28393858
10. GAN (gigaxonin) E3 ligase and ATG16L1: master and commander of autophagosome production.  |  Bomont, P. 2019. Autophagy. 15: 1650-1652. PMID: 31179825

The preferred Gigaxonin antibody is Gigaxonin Antibody (F-3): sc-376173.